Business Description

Description
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.83
Interest Coverage 53.39
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 16.68
Distress
Grey
Safe
Beneish M-Score -2.68
Manipulator
Not Manipulator

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.54
Quick Ratio 4.68
Days Inventory 149.92
Days Sales Outstanding 61.72
Days Payable 46.64

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 3.2

Financials

FRA:TL1's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Thoratec Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 412.661
EPS (TTM) (€) 0.612
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR (€) 0
20-Day SMA (€) 0
12-1 Month Momentum % 0
52-Week Range (€) 19.69 - 57.85
Shares Outstanding (Mil) 54.8

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Thoratec Corp Filings

Filing Date Document Date Form
No Filing Data

Thoratec Corp Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Thoratec Corp Frequently Asked Questions

What is Thoratec Corp(FRA:TL1)'s stock price today?
The current price of FRA:TL1 is €55.92. The 52 week high of FRA:TL1 is €57.85 and 52 week low is €19.69.
When is next earnings date of Thoratec Corp(FRA:TL1)?
The next earnings date of Thoratec Corp(FRA:TL1) is .
Does Thoratec Corp(FRA:TL1) pay dividends? If so, how much?
Thoratec Corp(FRA:TL1) does not pay dividend.

Press Release

Subject Date
No Press Release